{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:14:38Z","timestamp":1778832878398,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009878","name":"Regione del Veneto","doi-asserted-by":"publisher","award":["339\/12"],"award-info":[{"award-number":["339\/12"]}],"id":[{"id":"10.13039\/501100009878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgo.2020.09.009","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T08:44:28Z","timestamp":1600677868000},"page":"290-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience"],"prefix":"10.1016","volume":"12","author":[{"given":"Francesco","family":"Pierantoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Tierno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Bergo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Brunello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jgo.2020.09.009_bb0005","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2020.09.009_bb0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2007.12.006","article-title":"Management of Frail and not-Frail elderly cancer patients in a hospital-based geriatric oncology program","volume":"66","author":"Basso","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"10.1016\/j.jgo.2020.09.009_bb0015","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.009_bb0020","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res."},{"issue":"2","key":"10.1016\/j.jgo.2020.09.009_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jgo.2020.09.009_bb0030","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2020.09.009_bb0035","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.009_bb0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2008.08.002","article-title":"Aapro M; SIOG taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce","volume":"69","author":"Bellmunt","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"10.1016\/j.jgo.2020.09.009_bb0045","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2014.55.4246","article-title":"Targeted therapy in older patients with solid tumors","volume":"32","author":"Kelly","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2020.09.009_bb0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/annonc\/mds431","article-title":"Safety and activity of sunitinib in elderly patients (\u2265 70 years) with metastatic renal cell carcinoma: a multicenter study","volume":"24","author":"Brunello","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2020.09.009_bb0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clgc.2013.11.005","article-title":"Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis","volume":"12","author":"De Giorgi","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.jgo.2020.09.009_bb0060","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","article-title":"Escudier B; Rainbow group. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis","volume":"26","author":"Bracarda","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2020.09.009_bb0065","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-017-0628-2","article-title":"Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting Pazopanib or Sunitinib treatment: a retrospective Medicare claims analysis","volume":"34","author":"Vogelzang","year":"2017","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.jgo.2020.09.009_bb0070","first-page":"424","article-title":"Multidimensional geriatric evaluation in elderly cancer patients: a practical approach","volume":"13","author":"Basso","year":"2004","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"11A","key":"10.1016\/j.jgo.2020.09.009_bb0075","first-page":"221","article-title":"General guidelines for the management of older patients with cancer","volume":"14","author":"Balducci","year":"2000","journal-title":"Oncology (Williston Park)"},{"issue":"22","key":"10.1016\/j.jgo.2020.09.009_bb0080","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and Management of Vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.009_bb0085","doi-asserted-by":"crossref","unstructured":"Lombardi G, Bergo E, Caccese M, Padovan M, Bellu L, Brunello A, Zagonel V. Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients. Cancers (Basel). 2019 Oct 9;11(10). pii: E1509. doi: https:\/\/doi.org\/10.3390\/cancers11101509. PubMed PMID: 31600898; PubMed Central PMCID: PMC6826848.","DOI":"10.3390\/cancers11101509"},{"issue":"3","key":"10.1016\/j.jgo.2020.09.009_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Topinkova E; task force on CGA of the International Society of Geriatric Oncology. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.jgo.2020.09.009_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jgo.2020.09.009_bb0100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2020.09.009_bb0105","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2007.10.6583","article-title":"Aapro M; International Society of Geriatric Oncology Chemotherapy Taskforce. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature","volume":"25","author":"Lichtman","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2020.09.009_bb0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jgo.2018.12.008","article-title":"SIOG guidelines- essential for good clinical practice in geriatric oncology","volume":"10","author":"Dubianski","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2020.09.009_bb0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","article-title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium","volume":"65","author":"Ruiz-Morales","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2020.09.009_bb0120","doi-asserted-by":"crossref","unstructured":"Porta C, Paglino C, Imarisio I, Ganini C, Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer. 2011;2:333\u20138. Epub 2011 Ju.n 2.","DOI":"10.7150\/jca.2.333"},{"issue":"9","key":"10.1016\/j.jgo.2020.09.009_bb0125","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2020.09.009_bb0130","first-page":"e61","article-title":"The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jgo.2020.09.009_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00280-011-1814-6","article-title":"Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma","volume":"69","author":"Shin","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.009_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2008.01.001","article-title":"Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients","volume":"109","author":"Fader","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2020.09.009_bb0145","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/gerona\/glw234","article-title":"Screening for frailty in older patients with early-stage solid tumors: a prospective longitudinal evaluation of three different geriatric tools","volume":"72","author":"Biganzoli","year":"2017","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"10.1016\/j.jgo.2020.09.009_bb0150","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/glu046","article-title":"Incorporating biomarkers of frailty and senescence in cancer therapeutic trials","volume":"70","author":"Hubbard","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jgo.2020.09.009_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00133","article-title":"Digital health for geriatric oncology","volume":"2","author":"Fallahzadeh","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.jgo.2020.09.009_bb0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.jgo.2020.09.009_bb0165","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.jgo.2020.09.009_bb0170","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol."},{"issue":"19","key":"10.1016\/j.jgo.2020.09.009_bb0175","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Sharma P; CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.09.009_bb0180","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277\u20131290. doi: https:\/\/doi.org\/10.1056\/NEJMoa1712126.","DOI":"10.1056\/NEJMoa1712126"},{"key":"10.1016\/j.jgo.2020.09.009_bb0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","article-title":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","volume":"108","author":"Auvray","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4\u20135","key":"10.1016\/j.jgo.2020.09.009_bb0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euf.2017.11.008","article-title":"Immunotherapy in the elderly","volume":"3","author":"Lalani","year":"2017","journal-title":"Eur Urol Focus"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820304367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820304367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:01:49Z","timestamp":1778832109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820304367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1879406820304367"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.09.009","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}